IBD Precis™ is comprised of a comprehensive nine antibody panel targeting both microbial and autoantigen markers, analyzed through a proprietary algorithm that identifies serology patterns consistent and not consistent with IBD.
This test is a serologic test designed to reduce diagnostic uncertainty and accelerate decision-making for patients with suspected IBD. IBD Precis™ utilitzes novel biomarkers and an updated algorithm. See Prometheus Laboratories for futher test information.
Submit entire SST tube. DO NOT ALIQUOT.
IBD Precis™ is a serological aid in the diagnosis, classification and clinical assessment of inflammatory bowel disease (IBD). It uses proprietary biomarkers and an algorithm to distinguish patterns consistent or not consistent with IBD, differentiate Crohn's disease (CD) from ulcerative colitis (UC), and provides insights on colonic involvement and/or risk of complications. Biomarkers are assessed via several technology platforms including ELISA, chemiluminescence and indirect immunofluorescence integrated with DNase sensitivity analysis.